Novartis AG Sees $590 Million Charge Because of Drug Trial Stoppages for Antifungal Agent Mycograb as Well as Zalbin

Bloomberg -- Novartis AG is stopping development of two experimental medicines, a decision that will result in charges of about $590 million in charges in the third quarter.